For the year ending 2025-12-31, ALLO has $415,905K in assets. $123,363K in debts. $51,688K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 51,688 | |||
| Short-term investments | 198,522 | |||
| Prepaid expenses and other current assets | 7,539 | |||
| Total current assets | 257,749 | |||
| Long-term investments | 8,043 | |||
| Operating lease right-of-use asset | 39,888 | |||
| Property and equipment, net | 72,839 | |||
| Deposit placed in escrow | 23,479 | |||
| Restricted cash | 10,292 | |||
| Other long-term assets | 3,615 | |||
| Total assets | 415,905 | |||
| Accounts payable | 4,270 | |||
| Accrued and other current liabilities | 28,244 | |||
| Total current liabilities | 32,514 | |||
| Lease liability, noncurrent | 75,045 | |||
| Other long-term liabilities | 15,804 | |||
| Total liabilities | 123,363 | |||
| Common stock, 0.001 par value 400,000,000 shares authorized as of december31, 2025 and december31, 2024 229,413,523 and 212,210,597 shares issued and outstanding as of december31, 2025 and december31, 2024, respectively | 229 | |||
| Additional paid-in capital | 2,302,753 | |||
| Accumulated deficit | -2,010,709 | |||
| Accumulated other comprehensive gain (loss) | 269 | |||
| Total stockholders equity | 292,542 | |||
| Total liabilities and stockholders equity | 415,905 | |||
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)